Persistent Asset Partners Ltd Purchases New Shares in Nurix Therapeutics, Inc. $NRIX

Persistent Asset Partners Ltd acquired a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the second quarter, HoldingsChannel reports. The fund acquired 30,973 shares of the company’s stock, valued at approximately $751,000.

Several other large investors have also recently added to or reduced their stakes in NRIX. Larson Financial Group LLC boosted its position in shares of Nurix Therapeutics by 339.0% in the fourth quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock valued at $29,000 after acquiring an additional 1,190 shares during the period. California State Teachers Retirement System increased its position in Nurix Therapeutics by 2.2% during the fourth quarter. California State Teachers Retirement System now owns 68,019 shares of the company’s stock worth $1,290,000 after acquiring an additional 1,476 shares during the period. Intesa Sanpaolo Wealth Management acquired a new stake in Nurix Therapeutics in the 4th quarter worth about $31,000. Royal Bank of Canada raised its stake in Nurix Therapeutics by 17.6% in the 4th quarter. Royal Bank of Canada now owns 10,842 shares of the company’s stock worth $206,000 after purchasing an additional 1,623 shares in the last quarter. Finally, Arizona State Retirement System boosted its holdings in Nurix Therapeutics by 8.2% in the 4th quarter. Arizona State Retirement System now owns 21,990 shares of the company’s stock valued at $417,000 after purchasing an additional 1,674 shares during the period.

Nurix Therapeutics Stock Performance

Shares of NASDAQ:NRIX opened at $27.05 on Monday. The firm has a 50 day moving average of $22.33 and a 200-day moving average of $18.32. The stock has a market capitalization of $2.81 billion, a PE ratio of -7.84 and a beta of 1.79. Nurix Therapeutics, Inc. has a 12 month low of $8.19 and a 12 month high of $27.35.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). The firm had revenue of $9.04 million for the quarter, compared to the consensus estimate of $15.29 million. Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%. On average, research analysts predict that Nurix Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 4,761 shares of the firm’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total value of $115,977.96. Following the sale, the chief financial officer owned 40,166 shares of the company’s stock, valued at approximately $978,443.76. This trade represents a 10.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.00, for a total value of $107,880.00. Following the completion of the transaction, the insider owned 115,005 shares in the company, valued at approximately $2,300,100. The trade was a 4.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 25,314 shares of company stock valued at $589,361. Company insiders own 6.70% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Wells Fargo & Company lowered shares of Nurix Therapeutics from an “overweight” rating to a “hold” rating and decreased their target price for the stock from $28.00 to $25.00 in a research report on Monday, June 8th. BTIG Research reiterated a “buy” rating and issued a $32.00 price target on shares of Nurix Therapeutics in a research note on Friday, July 10th. Royal Bank Of Canada increased their price target on Nurix Therapeutics from $33.00 to $36.00 and gave the stock an “outperform” rating in a research report on Monday, August 10th. UBS Group raised their price objective on Nurix Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Finally, Robert W. Baird lifted their price objective on Nurix Therapeutics from $26.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $34.21.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.